Cost-Effectiveness Analysis Of Primary HPV Screening With Dual-Stain Cytology Triage In The Cervical Cancer Screening Program Of Belgium
OBJECTIVES: Previously we have shown that primary HPV screening with dual-stain cytology triage reduced the incidence of cervical cancer 36 % and the mortality by 40 %. Our objective is to determine the cost-effectiveness of dual-stain cytology triage in the 2017 cervical cancer screening program of...
Gespeichert in:
Veröffentlicht in: | Value in health 2017-10, Vol.20 (9), p.A578 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 9 |
container_start_page | A578 |
container_title | Value in health |
container_volume | 20 |
creator | Vandeweyer, K Tjalma, W |
description | OBJECTIVES: Previously we have shown that primary HPV screening with dual-stain cytology triage reduced the incidence of cervical cancer 36 % and the mortality by 40 %. Our objective is to determine the cost-effectiveness of dual-stain cytology triage in the 2017 cervical cancer screening program of Belgium. METHODS: The age group for the cervical cancer screening program is 25-65 years with a 3- years interval. Current practice is liquid based cytology (LBC) with reflex HPV testing for ASCUS.The proposed practice is primary HPV screening with reflex dual-stain cytology. The calculations are based on the honorarium of 2017. The cost calculation is based on screening, diagnostics and treatment. RESULTS: The cost for a HPV test is 35 €t for dual-stain cytology is 60 € and for LBC is 28,41 €. The transition from the current practice to the proposed practice will lead to an increase in costs the first three years (4.1 M €, 4.7 M € and 4.7 M €) and a decrease in the fourth (14.3 M €) and fifth (14.8 M €) year. Likewise screening in the 6th, 7th and 8th years will have an increase of respectively 2.2 M €, 3.5 M € and 3.5 M €. The 9th and the 10th year there is a decrease of 13.5 M € and 14 M €. CONCLUSIONS: Primary HPV screening program with dual-stain cytology triage can lead to a 5-years screening interval with a budget cost reduction after 5 years of almost 15 M €. |
doi_str_mv | 10.1016/j.jval.2017.08.1021 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2113728462</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2113728462</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1671-c1a411830dbaf838523d2dd6d609530a9111e207b5c0b8b2299bf61e6fbd63863</originalsourceid><addsrcrecordid>eNpNkFFLwzAUhYsoOKe_wJeAz525SZumj7NONxhssKmPIW2TLqVrZ9IO-g_82bbMB1_uvVwO53A-z3sEPAMM7LmclWdZzQiGaIb58CNw5U0gJIEfRJReDzeOuU8xhLfenXMlxphREk68n6Rxrb_QWmWtOataOYfmtax6ZxzaaLS15ihtj5bbT7TLrFK1qQv0ZdoDeu1k5e9aaWqU9G1TNUWP9tbIQqFVjfYHhRJlzyaTFUpknSn7z2Brm8LK45jwoqrCdMd770bLyqmHvz31Pt4W-2Tprzfvq2S-9jNgEQxTBgCc4jyVmlMeEpqTPGc5w3FIsYwBQBEcpWGGU54SEsepZqCYTnNGOaNT7-nie7LNd6dcK8qms0NjJwgAjQgPGBlU9KLKbOOcVVqcLiAEYDEiF6UYkYsRucBcjMjpLx2adYc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2113728462</pqid></control><display><type>article</type><title>Cost-Effectiveness Analysis Of Primary HPV Screening With Dual-Stain Cytology Triage In The Cervical Cancer Screening Program Of Belgium</title><source>Elsevier ScienceDirect Journals Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><creator>Vandeweyer, K ; Tjalma, W</creator><creatorcontrib>Vandeweyer, K ; Tjalma, W</creatorcontrib><description>OBJECTIVES: Previously we have shown that primary HPV screening with dual-stain cytology triage reduced the incidence of cervical cancer 36 % and the mortality by 40 %. Our objective is to determine the cost-effectiveness of dual-stain cytology triage in the 2017 cervical cancer screening program of Belgium. METHODS: The age group for the cervical cancer screening program is 25-65 years with a 3- years interval. Current practice is liquid based cytology (LBC) with reflex HPV testing for ASCUS.The proposed practice is primary HPV screening with reflex dual-stain cytology. The calculations are based on the honorarium of 2017. The cost calculation is based on screening, diagnostics and treatment. RESULTS: The cost for a HPV test is 35 €t for dual-stain cytology is 60 € and for LBC is 28,41 €. The transition from the current practice to the proposed practice will lead to an increase in costs the first three years (4.1 M €, 4.7 M € and 4.7 M €) and a decrease in the fourth (14.3 M €) and fifth (14.8 M €) year. Likewise screening in the 6th, 7th and 8th years will have an increase of respectively 2.2 M €, 3.5 M € and 3.5 M €. The 9th and the 10th year there is a decrease of 13.5 M € and 14 M €. CONCLUSIONS: Primary HPV screening program with dual-stain cytology triage can lead to a 5-years screening interval with a budget cost reduction after 5 years of almost 15 M €.</description><identifier>ISSN: 1098-3015</identifier><identifier>EISSN: 1524-4733</identifier><identifier>DOI: 10.1016/j.jval.2017.08.1021</identifier><language>eng</language><publisher>Lawrenceville: Elsevier Science Ltd</publisher><subject>Cancer screening ; Cellular biology ; Cervical cancer ; Cost analysis ; Cost control ; Cost reduction ; Cytology ; Human papillomavirus ; Medical screening ; Medical treatment ; Mortality ; Triage</subject><ispartof>Value in health, 2017-10, Vol.20 (9), p.A578</ispartof><rights>Copyright Elsevier Science Ltd. Oct/Nov 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1671-c1a411830dbaf838523d2dd6d609530a9111e207b5c0b8b2299bf61e6fbd63863</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,30999</link.rule.ids></links><search><creatorcontrib>Vandeweyer, K</creatorcontrib><creatorcontrib>Tjalma, W</creatorcontrib><title>Cost-Effectiveness Analysis Of Primary HPV Screening With Dual-Stain Cytology Triage In The Cervical Cancer Screening Program Of Belgium</title><title>Value in health</title><description>OBJECTIVES: Previously we have shown that primary HPV screening with dual-stain cytology triage reduced the incidence of cervical cancer 36 % and the mortality by 40 %. Our objective is to determine the cost-effectiveness of dual-stain cytology triage in the 2017 cervical cancer screening program of Belgium. METHODS: The age group for the cervical cancer screening program is 25-65 years with a 3- years interval. Current practice is liquid based cytology (LBC) with reflex HPV testing for ASCUS.The proposed practice is primary HPV screening with reflex dual-stain cytology. The calculations are based on the honorarium of 2017. The cost calculation is based on screening, diagnostics and treatment. RESULTS: The cost for a HPV test is 35 €t for dual-stain cytology is 60 € and for LBC is 28,41 €. The transition from the current practice to the proposed practice will lead to an increase in costs the first three years (4.1 M €, 4.7 M € and 4.7 M €) and a decrease in the fourth (14.3 M €) and fifth (14.8 M €) year. Likewise screening in the 6th, 7th and 8th years will have an increase of respectively 2.2 M €, 3.5 M € and 3.5 M €. The 9th and the 10th year there is a decrease of 13.5 M € and 14 M €. CONCLUSIONS: Primary HPV screening program with dual-stain cytology triage can lead to a 5-years screening interval with a budget cost reduction after 5 years of almost 15 M €.</description><subject>Cancer screening</subject><subject>Cellular biology</subject><subject>Cervical cancer</subject><subject>Cost analysis</subject><subject>Cost control</subject><subject>Cost reduction</subject><subject>Cytology</subject><subject>Human papillomavirus</subject><subject>Medical screening</subject><subject>Medical treatment</subject><subject>Mortality</subject><subject>Triage</subject><issn>1098-3015</issn><issn>1524-4733</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNpNkFFLwzAUhYsoOKe_wJeAz525SZumj7NONxhssKmPIW2TLqVrZ9IO-g_82bbMB1_uvVwO53A-z3sEPAMM7LmclWdZzQiGaIb58CNw5U0gJIEfRJReDzeOuU8xhLfenXMlxphREk68n6Rxrb_QWmWtOataOYfmtax6ZxzaaLS15ihtj5bbT7TLrFK1qQv0ZdoDeu1k5e9aaWqU9G1TNUWP9tbIQqFVjfYHhRJlzyaTFUpknSn7z2Brm8LK45jwoqrCdMd770bLyqmHvz31Pt4W-2Tprzfvq2S-9jNgEQxTBgCc4jyVmlMeEpqTPGc5w3FIsYwBQBEcpWGGU54SEsepZqCYTnNGOaNT7-nie7LNd6dcK8qms0NjJwgAjQgPGBlU9KLKbOOcVVqcLiAEYDEiF6UYkYsRucBcjMjpLx2adYc</recordid><startdate>201710</startdate><enddate>201710</enddate><creator>Vandeweyer, K</creator><creator>Tjalma, W</creator><general>Elsevier Science Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope></search><sort><creationdate>201710</creationdate><title>Cost-Effectiveness Analysis Of Primary HPV Screening With Dual-Stain Cytology Triage In The Cervical Cancer Screening Program Of Belgium</title><author>Vandeweyer, K ; Tjalma, W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1671-c1a411830dbaf838523d2dd6d609530a9111e207b5c0b8b2299bf61e6fbd63863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Cancer screening</topic><topic>Cellular biology</topic><topic>Cervical cancer</topic><topic>Cost analysis</topic><topic>Cost control</topic><topic>Cost reduction</topic><topic>Cytology</topic><topic>Human papillomavirus</topic><topic>Medical screening</topic><topic>Medical treatment</topic><topic>Mortality</topic><topic>Triage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vandeweyer, K</creatorcontrib><creatorcontrib>Tjalma, W</creatorcontrib><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><jtitle>Value in health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vandeweyer, K</au><au>Tjalma, W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-Effectiveness Analysis Of Primary HPV Screening With Dual-Stain Cytology Triage In The Cervical Cancer Screening Program Of Belgium</atitle><jtitle>Value in health</jtitle><date>2017-10</date><risdate>2017</risdate><volume>20</volume><issue>9</issue><spage>A578</spage><pages>A578-</pages><issn>1098-3015</issn><eissn>1524-4733</eissn><abstract>OBJECTIVES: Previously we have shown that primary HPV screening with dual-stain cytology triage reduced the incidence of cervical cancer 36 % and the mortality by 40 %. Our objective is to determine the cost-effectiveness of dual-stain cytology triage in the 2017 cervical cancer screening program of Belgium. METHODS: The age group for the cervical cancer screening program is 25-65 years with a 3- years interval. Current practice is liquid based cytology (LBC) with reflex HPV testing for ASCUS.The proposed practice is primary HPV screening with reflex dual-stain cytology. The calculations are based on the honorarium of 2017. The cost calculation is based on screening, diagnostics and treatment. RESULTS: The cost for a HPV test is 35 €t for dual-stain cytology is 60 € and for LBC is 28,41 €. The transition from the current practice to the proposed practice will lead to an increase in costs the first three years (4.1 M €, 4.7 M € and 4.7 M €) and a decrease in the fourth (14.3 M €) and fifth (14.8 M €) year. Likewise screening in the 6th, 7th and 8th years will have an increase of respectively 2.2 M €, 3.5 M € and 3.5 M €. The 9th and the 10th year there is a decrease of 13.5 M € and 14 M €. CONCLUSIONS: Primary HPV screening program with dual-stain cytology triage can lead to a 5-years screening interval with a budget cost reduction after 5 years of almost 15 M €.</abstract><cop>Lawrenceville</cop><pub>Elsevier Science Ltd</pub><doi>10.1016/j.jval.2017.08.1021</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1098-3015 |
ispartof | Value in health, 2017-10, Vol.20 (9), p.A578 |
issn | 1098-3015 1524-4733 |
language | eng |
recordid | cdi_proquest_journals_2113728462 |
source | Elsevier ScienceDirect Journals Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Applied Social Sciences Index & Abstracts (ASSIA) |
subjects | Cancer screening Cellular biology Cervical cancer Cost analysis Cost control Cost reduction Cytology Human papillomavirus Medical screening Medical treatment Mortality Triage |
title | Cost-Effectiveness Analysis Of Primary HPV Screening With Dual-Stain Cytology Triage In The Cervical Cancer Screening Program Of Belgium |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A18%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-Effectiveness%20Analysis%20Of%20Primary%20HPV%20Screening%20With%20Dual-Stain%20Cytology%20Triage%20In%20The%20Cervical%20Cancer%20Screening%20Program%20Of%20Belgium&rft.jtitle=Value%20in%20health&rft.au=Vandeweyer,%20K&rft.date=2017-10&rft.volume=20&rft.issue=9&rft.spage=A578&rft.pages=A578-&rft.issn=1098-3015&rft.eissn=1524-4733&rft_id=info:doi/10.1016/j.jval.2017.08.1021&rft_dat=%3Cproquest_cross%3E2113728462%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2113728462&rft_id=info:pmid/&rfr_iscdi=true |